Sona Nanotech CEO David Regan joined Steve Darling from Proactive to announce a significant milestone in the company’s clinical journey—the first patient dosing has been successfully completed in the early feasibility study of its Targeted Hyperthermia Therapy (THT) for advanced melanoma. This first-in-human dosing marks the culmination of years of preclinical research and development, representing a pivotal step toward validating Sona’s novel cancer treatment approach. The study is designed to assess the safety, tolerability, and early efficacy signals of THT, focusing on its ability to inhibit tumor growth and stimulate immune system engagement—particularly in patients who have not responded to standard-of-care immunotherapy treatments. The trial involves two treatments of Sona’s THT administered one week apart, targeting patients with advanced melanoma who are currently on—or have previously received—immunotherapy protocols but experienced disease progression or inadequate response. Initial readouts are expected later this summer, with final trial results anticipated in the fall. Regan also revealed the company’s plans for a second, more expansive human trial to follow shortly after, pending feedback and further engagement with regulatory authorities. Additionally, Sona intends to publish the study’s findings in a peer-reviewed scientific journal, contributing to the broader body of oncology research. Sona’s Targeted Hyperthermia Therapy uses gold nanorods designed to accumulate in tumors, which are then selectively heated using infrared light to disrupt cancerous tissue while potentially amplifying the immune system’s response—offering a non-invasive complement or alternative to existing immunotherapy options that often come with limited response rates or harsh side effects. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTherapy #GoldNanorods #FDAApproval #BiotechNews #Immunotherapy #ClinicalTrials #Nanomedicine #MelanomaTreatment #CancerResearch #THTTherapy #ClinicalTrials #CancerDevice #Immunotherapy #BiotechNews #LateStageCancer #ProactiveInvestors